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Pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-α
(TNF-α), are thought to play a fundamental role in the pathogenesis of depression
within a subset of individuals. However, the involvement of IL-1β has not been as
consistently linked to depression, possibly owing to difficulties in detecting this cytokine
in blood samples or that changes in circulating levels might only be apparent in a
subgroup of patients who have experienced early-life adversity. From this perspective,
the association between early-life adversity and depressive illness might depend on
genetic variants regulating IL-1β activity. Considering the inflammatory-depression link,
and that women are twice as likely to experience depression compared to men, the
current study (N = 475 university students) examined the moderating role of three
independent cytokine single nucleotide polymorphisms (SNPs; IL-1β rs16944, IL-6
rs1800795 SNP, TNF-α rs1800629) in the relationship between early-life adversity and
depressive symptoms, and whether these relations differed between males and females.
The relation between childhood adversity and depressive symptoms was moderated
by the IL-1β SNP, and further varied according to sex. Specifically, among females,
higher childhood maltreatment was accompanied by elevated depressive symptoms
irrespective of the IL-1β SNP, but among males, this relationship was particularly
pronounced for those carrying the GG genotype of the IL-1β SNP. These findings suggest
that, in the context of early life adversity, genetic variations of IL-1β functioning are related
to depressive symptomatology and this may vary amongmales and females. The present
study also, more broadly, highlights the importance of considering the confluence of
experiential factors (e.g., early life adversity) and personal characteristics (e.g., sex and
genetics) in understanding depressive disorders, an approach increasingly recognized in
developing personalized treatment approaches to this illness.
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INTRODUCTION
The role of inflammation in the pathogenesis of depression
is well-established (1, 2). Depressed individuals display
elevated circulating pro-inflammatory cytokine levels (3)
and administering pro-inflammatory cytokines to adults (e.g.,
during the course of treatment for hepatitis C and for some
types of cancer) induces symptoms of depression, an effect
that could be reversed by antidepressants (4). A meta-analysis
comprising 58 studies indicated that interleukin (IL)-6 and the
acute phase reactant C-reactive protein (CRP) were elevated in
major depressive disorder, and to a lesser extent, tumor necrosis
factor (TNF)-α (5). Treatment with antidepressants, as expected,
was accompanied by reduced peripheral IL-6, TNF-α, and the
anti-inflammatory IL-10 (6).
When considering the link between IL-1β and depression,
the results have been mixed. Some meta-analyses do not find
an overall association between IL-1β and major depression (3,
5, 7), although it was suggested that this could be due to
measurement issues as concentrations of IL-1β are very low in
blood (5). Moreover, no differences were found in basal IL-
1β levels in a recent paper with MDD patients, but proteins
upstream IL-1β production were elevated (8). However, others
have reported elevated IL-1β levels in major depression (9),
and a separate meta-analysis found elevated IL-1β in patients
affected with major depressive disorder, although, this was only
when the studies included were rated as having high quality
methodologies (10). It was suggested that IL-1β changes may
be apparent in a subgroup of patients, including individuals
with a history of childhood trauma (10). Consistent with this
perspective, early-life adversity might be centrally involved in the
relationship between depression and inflammation by promoting
changes to inflammatory signaling (11). In this regard, females
who reported sexual abuse in adolescence displayed higher
plasma levels of the pro-inflammatory cytokine IL-6 (12). Scores
on an early trauma inventory scale were positively associated
with serum IL-6, TNF-α and IL-1β levels (13), and depressed
individuals with experiences of childhood trauma displayed
higher peripheral cytokine levels compared to individuals with
major depressive disorder who did not experience childhood
trauma (14).
Beyond plasma cytokine levels, genetic variants of pro-
inflammatory cytokines that can alter gene transcription and
thereby affect inflammatory proteins, including IL-1β, have been
associated with a wide range of physical and psychological
disturbances, such as major depression (15, 16). Secretion
of IL-1β protein can be influenced by a single nucleotide
polymorphism (SNP), rs16944 located in the promoter region of
the gene (17). However, currently there are inconsistent reports
about whether the GG genotype (18) or the A/A genotype
(19) is associated with elevated IL-1β levels. Moreover, other
reports have suggested that the functional role of this SNP might
depend on promoter region haplotypes (17, 20). Despite the poor
understanding of the functionality of this SNP, it has been tied
to a number of psychological outcomes. Specifically, individuals
carrying two copies of the G allele, were found to have an early
age of onset of depression (21), higher depressive symptoms
and poorer response to antidepressant treatment (22–24),
elevated cortisol levels following dexamethasone (25), and greater
depressive symptoms following chronic interpersonal stressor
encounters (26). However, there have also been some conflicting
findings, such that an elevated risk of depression among the
minor allele A carriers for individuals with schizophrenia
spectrum disorders (27), Alzheimer’s disease (28), and following
childhood adversity (29).
Altered IL-6 expression has been linked to the IL-6 rs1800795
SNP, which is also located in the promoter region of the gene
(30, 31). However, this SNP has been inconsistently linked to
depression, in that individuals homozygous for the G allele
exhibited an increase in depressive symptoms (32), whereas
no association was found between this SNP and depression in
other reports (33–35). It was found, however, that following
interpersonal stress (26), and recent negative events (36), the G-
carriers of this IL-6 SNP expressed fewer depressive symptoms
relative to CC homozygotes. The TNF-α rs1800629 SNP located
in the promoter region has also been inconsistently linked
to depression and a recent meta-analysis found no significant
association to depression (37). Only one previous investigation
examined the TNF-α SNP in association to interpersonal stress
and depression, and found no moderating role of the TNF-α
SNP (26).
As women are approximately twice as likely to be diagnosed
with depression (38), and report greater severity and increased
symptoms compared to men (39), the pathophysiology of
depression might also differ by sex. In fact, a large-scale
gene expression study revealed multiple transcription changes
in opposite directions between men and women with major
depressive disorder (40).
Considering the discrepant findings regarding the IL-1β SNP,
the primary aim of the current study was to examine the
moderating role of the IL-1β SNP and that of IL-6, and TNF-
α in the relation between early life adversity and depressive
symptoms, and to determine whether any such effects would
be moderated by sex. In the present investigation we chose
to assess these factors in a sample of university students, as
it has long been known that ∼15–20% of students entering
post-secondary educational institutions may have undiagnosed
or subsyndromal symptoms of depression and anxiety (41).
Moreover, early-life adverse experiences, such as childhood
abuse and neglect, have been increasingly reported by college
students and are thought to be contributing to large increases
in the number of students presenting at university counseling
services (42, 43). Given the considerable role for early life
negative experiences in the evolution of adult depression, it
was hypothesized that the GG carriers for the IL-1β SNP
would display elevated depression scores following childhood
maltreatment, although it was uncertain whether women or
men might be more affected in this regard. Moreover, it was
expected that the G-carriers of the IL-6 SNP would be linked
to fewer depressive symptoms following childhood maltreatment
compared to individuals with the CC genotype, but similarly,
a sex effect was uncertain. The currently available data do
not justify a hypothesis that early-life adversity and the TNF-
α SNP would be associated with adult depression, but this
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SNP was included in the present analysis to replicate previous
null findings.
METHODS
Procedure
Students were recruited through the university’s online
computerized research system. Participants provided informed
written consent, following which they completed measures
of current depressive symptoms, experiences of early-life
maltreatment, and a series of demographic questions (e.g., age,
sex, and ethnicity). After completing the questionnaires, saliva
samples were collected for later genotyping. Participants were
debriefed and compensated with course credit. This study was
approved by the Carleton University Ethics Committee for
Psychological Research.
Genotyping
Norgen collection kits (Norgen Biotek Corp., Thorold, Ontario
Canada) were used for the collection of saliva samples for
genotyping. Genomic DNA was extracted from the sample
collection kit according to the manufacturer’s instructions
and diluted to approximately equal concentration (10 ng/µL).
Genotyping was performed at the McGill University and
Génome Québec Innovation Center (Montreal, Canada).
Polymerase chain reaction (PCR) was used to amplify the DNA,
and QIAXcel determined amplification status. To remove all
unincorporated dNTPs, shrimp alkaline phosphatase was used.
One probe per marker was used to do a single base extension
and the product was desalted using 6mg of resin. Products
were spotted on a Sequenom 384-well chip using a Samsung
Nanodispenser and then read by a Mass Spectrometer. A manual
analysis was done for each marker. Primer sequences were: IL-1β
forward: ACGTTGGATGCTGTCTGTATTGAGGGTGTG,
IL-1β reverse: ACGTTGGATGATTTTCTCCTCAGAGGCTCC,
IL-1β probe: GTGCTGTTCTCTGCCTC, TNF-α forward:
ACGTTGGATGTTCTGGGCCACTGACTGATT, TNF-α
reverse: ACGTTGGATGAAGGAAACAGACCACAGACC,
TNF-α probe: AGGCTGAACCCCGTCC, IL-6 forward:
ACGTTGGATGGATTGTGCAATGTGACGTCC, IL-6 reverse:
ACGTTGGATGAGTGGTTCTGCTTCTTAGCG, and IL-6
probe: TGTGACGTCCTTTAGCAT.
Measures
Depressive Symptoms
The 21-item Beck Depression inventory (BDI) (44) was used to
assess depressive symptoms. For each item, participants selected
one of four response options, which ranged from mild to severe
indicators of depressive symptomatology. Total scores were
calculated by summing across all items (α = 0.90).
General Health
Participants completed a one-item question asking, “In your
opinion, how do you describe your health,” which ranged from one
(poor) to five (excellent). This question was assessed to examine
how BDI scores map onto other aspects of life/functionality.
As expected, it was found that poorer health related to higher
depressive symptoms, r=−0.476, p< 0.001.
Childhood Maltreatment
The 31-item Childhood Maltreatment Questionnaire (short
form) (45) assessed levels of early life adversity, including
psychological (α = 0.95), physical (α = 0.90), and sexual abuse
(α = 0.97) as well as neglect (α = 0.85). Each item is rated from 1
(never) to 5 (very often) indicating the frequency of experiences.
Total scores were calculated by obtaining the mean across all
items (α = 0.95).
Statistical Analyses
Statistical analyses were performed using SPSS for Windows
24.0 (SPSS Science, Chicago, Illinois, USA). Analyses assessing
genotype differences on childhood maltreatment and depression
scores were performed using a one-way analysis of variance
(ANOVA), followed by Bonferroni corrected t-tests for any
significant outcomes. Sex differences were examined using
independent samples t-tests. Correlational analysis was
performed using Pearson product moment correlations. To
examine the moderating role of genotype and sex on the
relationship between childhood maltreatment and depression
scores, and any possible 3-way interactions, PROCESS (model 3)
was used (46), in which moderations are tested in a single model.
To be sure findings were not influenced by medications, such
as anti-depressants, medications were included as a covariate
in PROCESS and effects remained unchanged. Although it is
ideal to keep all three genotypes separate whenever possible,
as we have previously discussed in relation to OXTR genes
[see (47) for a discussion on this topic], moderation analyses
require a dichotomous moderator. For moderation analyses
genotypes were collapsed into two groups to perform dominant
tests because of power issues. A power calculation conducted
using on online A-Prior sample size calculator for a Hierarchical
Multiple Regression using three predictors in set A (Gender,
Il-1B, and Childhood Maltreatment), one predictor in set B
(3-way interaction term), a desired power level of 0.8, a p-value
of 0.05 and the anticipated small effect size of 0.02. The power
calculator provided a desired sample size of N = 388 (48). For
the three main models conducted (one for each of the 3 SNPs),
corrections for multiple testing were made such that models
were considered significant if they were less than p= 0.0167, and
effects remained significant.
RESULTS
Participants and Descriptive Information
The original sample comprised 925 Carleton University first year
students of various ethnic backgrounds. Population stratification
effects were found, in which the IL-1β rs16944, TNF-α rs1800629,
and IL-6 rs1800795 genotype distributions significantly differed
according to ethnic groups, χ2(16) = 77.0, p< 0.001, χ
2
(16) = 39.1,
p = 0.001, and χ2(16) = 209.5, p < 0.001, respectively. As an
example of these differences, 97.3% of the Asian participants
(Chinese, Japanese, Korean) displayed the GG genotype for the
IL-6 SNP, whereas, only 36.3% of participants who reported
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European white ethnicity had this genotype. Moreover, 89.9% of
participants who identified as black (African, Haitian, Jamaican,
and Somali) displayed the GG genotype for IL-6 SNP, which was
more in-line with Asian participants, whereas individuals who
reported South Asian ethnicity (East Indian, Pakistani, Punjabi,
and Sri Lankan) had 59.4% GG carriers. This example highlights
the large discrepancies of genotype distributions across ethnic
groups and the importance of conducting gene x environment
analyses within a single homogeneous ethnic group. Accordingly,
the current study only examined the largest homogeneous ethnic
group, which comprised 475 individuals of European white
ethnicity. Of these individuals, there were 343 females and 132
males with a mean age of 19.45 years (SE = 0.11, range = 17–
35 years).
Among participants five individuals were taking anti-
inflammatory medications (1.1%), 20 individuals were taking
anti-depressant medication (4.2%), six individuals were taking
anti-anxiety medications (1.3%), and 34.9% reported other
medications, which largely included birth control, asthma and
allergy medications.
Genotype Distributions and Differences
Six individuals could not be genotyped for the IL-1β rs16944
SNP and the TNF- α rs1800629 SNP, whereas four individuals
could not be genotyped for the IL-6 SNP, rs1800795. Genotype
distributions and Hardy-Weinberg Equilibrium expectations are
represented in Table 1.
TABLE 1 | Genotype frequencies, distributions, and Hardy-Weinberg equilibrium
expectations.
Genotype
distributions
GG GA AA Hardy Weinberg
equilibrium
IL-1β (total) 197 (42%) 225 (48%) 47 (10%) χ2
(1)
= 2.22,
p > 0.05
Males 54 (41.2%) 61 (46.6%) 16 (12.2%) χ2
(1)
= 0.04,
p > 0.05
Females 143 (42.3%) 164 (48.5%) 31 (9.2%) χ2
(1)
= 2.74,
p > 0.05
GG GA AA
TNF-α (total) 324 (69.1%) 133 (28.4%) 12 (2.6%) χ2
(1)
= 0.1,
p > 0.05
Males 93 (71.0%) 34 (26.0%) 4 (3.1%) χ2
(1)
= 0.17,
p > 0.05
Females 231 (68.1%) 99 (29.3%) 8 (2.4%) χ2
(1)
= 0.47,
p > 0.05
GG GC CC
IL-6 (total) 171 (36.3%) 225 (47.8%) 75 (15.9%) χ2
(1)
= 0,
p > 0.05
Males 39 (38.7%) 67 (46.3%) 24 (15.0%) χ2
(1)
= 0.26,
p > 0.05
Females 132 (30.0%) 158 (51.5%) 51 (18.5%) χ2
(1)
= 0.11,
p > 0.05
There were no differences in childhood maltreatment total
scores across genotypes for the IL-1β, F(2,466) = 0.69, p = 0.50,
TNF-α, F(2,466) = 0.14, p = 0.87, or IL-6 SNPs, F(2,468) = 0.41,
p = 0.67. Depression scores, however, varied with the IL-
1β genotype, F(2,466) = 4.00, p = 0.02, η
2
= 0.02, with GG
carriers reporting more severe depressive symptoms (M = 10.23,
SE = 0.57), compared to GA carriers (M = 8.11, SE = 0.54),
p = 0.02, whereas AA carriers did not significantly differ
compared to the other groups. Depression scores, in contrast, did
not vary based on the TNF-α genotypes, F(2,466) = 0.28, p= 0.76,
or the IL-6 SNP, F(2,468) = 0.84, p = 0.43. Table 2 shows means
for genotype groups collapsed according to the dominant model.
Correlations
As expected, females report more severe depressive symptoms
than males, t(1, 473) = 3.19, p = 0.002 (females M = 9.92, SE
0.44; males M = 7.32, SE 0.65), and also reported higher levels
of childhood maltreatment, t(1, 332.0) = 2.52, p = 0.012 (females:
M = 1.53, SE 0.03; males: M = 1.41, SE 0.04). As shown
in Table 3, the relations between the childhood maltreatment
total scores and depressive symptoms were significant, as were
the relations between the different forms of maltreatment
and depressive scores (reports of sexual abuse were very
infrequent and as such, this subscale was not assessed as an
independent measure).
Moderation Analyses
To examine whether sex and cytokine SNPs moderated the
relationship between childhood maltreatment and depression
scores, moderation analyses were conducted separately for each
cytokine SNP. For IL-1β, the overall model was significant,
R2 = 0.26, F(7,461) = 23.11, p < 0.001, revealing interactions
between Childhood Maltreatment × IL-1β, p = 0.03, Childhood
Maltreatment × Sex, p = 0.005, and IL-1β × Sex, p = 0.003,
as well as a significant 3-way interaction between Childhood
TABLE 2 | Mean and standard deviation of childhood maltreatment and
depressive symptoms collapsed across genotype groups.
Genotype groups Childhood maltreatment
(M ± SD)
Depressive
symptoms (M ± SD)
IL-1β
Males (GG) 1.32 (±0.34) 6.78 (±7.66)
Males (GA/AA) 1.48 (±0.46) 7.74 (±7.37)
Females (GG) 1.59 (±0.63) 11.53 (±8.96)
Females (GA/AA) 1.49 (±0.56) 8.74 (±7.37)
TNF-α
Males (GG) 1.46 (±0.46) 8.04 (±8.00)
Males (GA/AA) 1.30 (±0.27) 5.63 (±5.75)
Females (GG) 1.51 (±0.59) 9.50 (±8.14)
Females (GA/AA) 1.57 (±0.60) 10.78 (±8.30)
IL-6
Males (GG) 1.42 (±0.33) 7.59 (±6.94)
Males (GC/CC) 1.40 (±0.45) 7.00 (±7.42)
Females (GG) 1.50 (±0.05) 10.32 (±0.74)
Females (GC/CC) 1.55 (±0.58) 9.65 (±8.00)
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TABLE 3 | Pearson correlations among childhood maltreatment total and
subscales and depressive symptoms.
1 2 3 4 5
1. Depressive symptoms ––––––
2. Childhood maltreatment (total score) 0.47** ––––––
3. Childhood physical abuse 0.31** 0.78** ––––––
4. Childhood psychological abuse 0.48** 0.96** 0.63** ––––––
5. Childhood neglect 0.41** 0.87** 0.65** 0.77** ––––––
**p < 0.001.
maltreatment × IL-1β × Sex, R2
change
= 0.01, F(1, 461) = 7.86,
p = 0.005. The findings of the 3-way interaction are
shown in Figure 1, wherein a positive relationship between
childhood maltreatment and depressive symptoms for females
was significant for both GG and A carriers of the IL-1β SNP,
B = 6.78, t = 7.27, p < 0.001, 95% CI [4.95, 8.61] and B = 6.16,
t = 6.84, p < 0.001, 95% CI [4.39, 7.93], respectively. For males,
the relationship between childhoodmaltreatment and depression
was also significant for both genotype carriers, however, it was
a much stronger effect for GG carriers, B = 15.17, t = 5.36, p
< 0.001, 95% CI [9.61, 20.73], compared to A carriers B = 4.55,
t = 2.60, p= 0.01, 95% CI [1.11, 7.98]. In fact, among males with
low levels of childhoodmaltreatment, depression scores were low
irrespective of the genotype. However, as levels of maltreatment
increased, depression scores were appreciably higher, and more
so among those with the GG alleles than among A carriers.
Due to the significant IL-1β SNP model when examining
total child maltreatment scores, we conducted follow-up
analyses for the different forms of abuse. Once more, 3-
way interactions between IL-1β x Sex and each of the
subscales of childhood maltreatment were evident: psychological
maltreatment, R2
change
= 0.01, F(1, 461) = 5.43, p = 0.02, neglect,
R2
change
= 0.01, F(1, 461) = 5.57, p = 0.02, and physical abuse,
R2
change
= 0.01, F(1, 461)= 4.34, p= 0.04. However, after correcting
for multiple testing, these effects were no longer considered
significant at p< 0.0167.
Analysis of the moderating relationships involving the TNF-
α and IL-6 SNPs indicated that none of these interactions
were significant.
DISCUSSION
The current study revealed that, although the effect size was
small, depressive symptoms were higher among individuals with
the GG genotype of the IL-1β rs16944 SNP, an outcome that
was most pronounced among those who experienced childhood
adversity. These findings align with earlier reports that the
GG carriers show an earlier age of onset of depression (21),
enhanced severity of depressive symptoms (24) and poorer
responses to antidepressants (22–24). Moreover, individuals with
the GG genotype also displayed greater depressive symptoms
following chronic interpersonal stressor experiences (26). Thus,
the current findings replicate this earlier report showing that
the relation between childhood maltreatment and depressive
symptoms was also stronger among individual homozygous
for the GG genotype. However, it has also been reported that
individuals with the GG genotype displayed lower depression
scores following childhood adversity (29). Why these differences
exist are uncertain, however, in Kovacs et al. report the relations
to depression were only apparent among individuals who
encountered themost marked childhood adversity. Maltreatment
scores in the current study weremodest and thus, comparisons or
generalizations beyond this population would be inappropriate.
As commonly observed, depressive symptoms were higher
in women than in men. Sex also interacted with the IL-
1β SNP and childhood maltreatment in predicting depressive
scores. Specifically, following maltreatment, males who carried
the GG genotype of the IL-1β SNP showed particularly
marked depressive symptoms. This finding appears to be in
line with research examining systemic inflammation and sex,
wherein a higher production of pro-inflammatory cytokines
were associated with increasing depressive symptoms for males,
however females exhibited reduced pro-inflammatory cytokines
as depressive symptoms increased (49). It appears that there are
gender differences in the relation between depressive symptoms
and inflammatory patterns. Additionally, there have been several
reports indicating that the sex differences in depression varied
with SNPs on genes other than those coding for cytokines. For
instance, the glucocorticoid receptor gene (NR3C1) SNP rs6195
was related to depression among females, but not males (50).
Moreover, there was a sex-dependent moderation of a functional
mineralocorticoid receptor (MA) haplotype in the relationship
between childhood maltreatment and depression, revealing that
males in the clinical sample were at increased risk of depression
(51). As well, among boys and girls that carried the short
allele of the serotonin transporter gene, 5-HTTLPR, displayed
opposite responses to environmental stressors (52). In line with
these reports, a meta-analysis suggested that pronounced gene
expression differences exist between men and women with major
depression, and even more relevant to the current findings is
the suggestion that treatments aimed at suppressing immune
function might be more appropriate for men with depression
compared to women (40).
These findings highlight the importance of considering
individual characteristics, such as sex, when examining
the link between genetic variants and depression, and the
treatment of this disorder. Personalized treatment approaches
extend beyond this to also recognize the importance of
contextual and environmental factors, such as early-
life stressful experiences (53). Early-life stressors and/or
trauma have been strongly linked to the later development
of depression and may interact with individual genetic
variants to contribute to depression (54). By example, it
was reported that interactions between early-life adversity
and the oxytocin receptor gene (OXTR) SNP rs5657
(55), and brain derived neurotrophic factor (BDNF) SNP
(56, 57) were linked to depressed mood. Interactions have
also been reported between early-life maltreatment and a
polymorphism in the promoter region of the serotonin
transporter gene (5-HTTLPR) (58). To be sure, considerable
controversy exists concerning the reliability of such reports
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FIGURE 1 | The 3-way interaction between childhood maltreatment, the IL-1β rs16944 SNP (GG vs. GA/AA) and sex in relation to depression scores. Females are
shown in the left graph and males are shown in the right graph.
(59), but it should be considered that there are differences
in sample characteristics and contexts, such as the timing
and type of stress experienced across studies, which
highlight the importance of accurate characterization of the
environmental exposures underlying the gene × environment
effects (54, 60).
In the current study general depressive symptoms were
examined, but it would be of particular interest to focus on
specific symptoms or subtypes of depression, such as atypical
depression, which might be differentially related to sex and/or
the cytokine SNPs. As well, specific cytokine SNPs that were
not tied to depression might be more strongly linked to suicide
behaviors. In this regard, the GG genotype of the TNF-α SNP,
rs1800629, was associated with increased risk for suicide attempts
among patients with major depressive disorder (61), even
though this TNF-α SNP was not linked to general depression
and depressive symptomatology (26, 37). The current findings
similarly did not show an association between this TNF-α SNP
and depressive scores.
Although there have been several reports indicating that
inflammatory factors, notably circulating IL-6 and TNF-α, were
associated with major depressive illness (5, 62), as previously
observed (33–35), the IL-6 rs1800795 SNP was not directly
related to depression scores in the present study. Moreover, the
IL-6 SNP did not interact with childhood maltreatment or sex
to predict depression symptoms. This differs from earlier reports
showing interactions between this SNP with interpersonal stress
(26), and recent negative events (36), in relation to depression.
Of course, early-life maltreatment ought to be distinguished
from recent and/or acute stressors, which could explain the non-
significant effects in the current study. Recently, this IL-6 SNP
has been found to influence antidepressant treatment outcomes
in major depressive patients, which might suggest a role for IL-
6 in treatment resistant depression (63). As described earlier,
support for IL-6 involvement in depression has also come from
the many reports showing elevated levels of peripheral IL-6
in depressed patients (5). However, plasma cytokine levels do
not necessary reflect levels of this cytokine within the brain.
There is, indeed, reason to believe that inflammatory factors
released from microglia (64, 65) may contribute to psychiatric
disorders, including depression (66). However, it is unlikely
that these cytokine variations can be detected in plasma, or
that circulating cytokine levels would parallel brain cytokine
variations [e.g., (67)].
There are several limitations associated with the current study.
Specifically, early-life maltreatment was based on retrospective
self-reports, and although this is common when examining
childhood adversity, reports might be biased by the individuals’
current affective state, and individuals could be unaware of
events that took place years earlier. The current study also
examined depressive symptoms among university students and
thus the findings cannot be generalized to a clinically depressed
population. Moreover, it should be noted that the mean scores
for both childhood maltreatment and depressive symptoms were
fairly low and the findings could differ within the context
of higher maltreatment and depressive scores. An additional
limitation concerned the relatively small sample size, even
though it was determined that the sample size for the current
study (N = 495 individuals of a homogeneous ethnicity)
provided sufficient power to detect small effects, and significant
effects survived correction formultiple testing. Due to population
stratification effects, we had to limit our analyses to the largest
homogenous ethnic group, which comprised individuals who
identified as European/white. A larger sample ideally might have
allowed for assessment of gene x environment variations among
other ethnic groups. This is particularly of interest when we
consider the importance of culture in personalized medicine
(68, 69). Moreover, there is a possibility that the different
cytokine SNPs assessed independently might be additively or
interactively linked to depressive symptoms. For instance it
has been reported that BDNF and 5-HTTLPR interactions
were additive in predicting lifetime depression diagnosis (70),
however, in the current sample we had limited power to add
additional factors to our model. It is also problematic that the
functionality of the IL-1β SNP is not well-understood (25).
It would have been ideal to measure the relation between
the rs16944 SNP frequency and gene expression levels (i.e.,
the expression quantitative trait loci [eQTLs; (71, 72)]. This
approach could potentially facilitate a better understanding of
the functional role of the IL-1β SNP. However, human eQTL
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studies typically involve analyses in blood-derived cells, as
opposed to the saliva samples that were used in the present
study, and it also appears that gene expression might vary
with different cell types (71). Despite the potential benefits of
eQTL analyses, the present data do not lend themselves to this
approach. Finally, the current study precludes any causal effects
to be inferred.
Together with earlier findings, the present report indicates
that the IL-1β rs16944 SNP was associated with depressive
symptoms. The current report shows that this relationship might
be dependent on environmental contexts, including early-life
maltreatment and individual characteristics, such as sex. In fact,
sex differences appear to be especially critical in the relation
between SNPs and depression, as new reports highlight gene-
expression changes in opposite directions for men and women
with major depression. These findings, together with other
reports, highlight the importance of the social determinants of
health when examining depression, an approach increasingly
recognized in personalized approaches to medicine.
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